Metformin versus lifestyle changes in treating women with polycystic ovary syndrome
Carregando...
Citações na Scopus
44
Tipo de produção
article
Data de publicação
2012
Editora
INFORMA HEALTHCARE
Indexadores
Título da Revista
ISSN da Revista
Título do Volume
Autores
Autor de Grupo de pesquisa
Editores
Coordenadores
Organizadores
Citação
GYNECOLOGICAL ENDOCRINOLOGY, v.28, n.3, p.182-185, 2012
Resumo
Objective: To compare the efficacy of metformin with that of lifestyle changes in patients with polycystic ovary syndrome (PCOS). Design: Prospective, randomized clinical trial of 40 women with PCOS to analyze the effects of metformin and lifestyle intervention treatments on menstrual pattern and hormone and metabolic profile. The duration of treatment was 6 months. Statistical analysis was done using Student's t-test. Results: Fifteen women in the metformin group and 12 in the lifestyle changes group completed the study. The menstrual pattern improved by similar to 67% in both groups. There was a significant decrease in waist circumference in the lifestyle changes group (101.8 +/- 3.9 and 95.1 +/- 3.6, at baseline and at 6 months of treatment, respectively; p<0.001) and in body mass index (BMI) in both groups. The predictor of menstrual pattern improvement was BMI. Conclusions: Both metformin and lifestyle changes may increase the number of menstrual cycles in PCOS. This effect was related to a decrease in BMI.
Palavras-chave
BMI, lifestyle, menstrual cycle, metformin, polycystic ovary syndrome
Referências
- Attia GR, 2001, FERTIL STERIL, V76, P517, DOI 10.1016/S0015-0282(01)01975-6
- Barcellos CRG, 2007, ARQ BRAS ENDOCRINOL, V51, P601
- Barcellos CRG, 2007, ARQ BRAS ENDOCRINOL, V51, P1104, DOI 10.1590/S0004-27302007000700013
- CARO JF, 1991, J CLIN ENDOCR METAB, V73, P691
- CHANG RJ, 1983, J CLIN ENDOCR METAB, V57, P356
- Despres JP, 2001, BRIT MED J, V322, P716, DOI 10.1136/bmj.322.7288.716
- Ehrmann DA, 1997, J CLIN ENDOCR METAB, V82, P524, DOI 10.1210/jc.82.2.524
- Harborne L, 2003, LANCET, V361, P1894, DOI 10.1016/S0140-6736(03)13493-9
- Hoeger KM, 2004, FERTIL STERIL, V82, P421, DOI 10.1016/j.fertnstert.2004.02.104
- Hollmann M, 1996, HUM REPROD, V11, P1884
- Huber-Buchholz MM, 1999, J CLIN ENDOCR METAB, V84, P1470, DOI 10.1210/jc.84.4.1470
- JACKSON RA, 1987, DIABETES, V36, P632, DOI 10.2337/diabetes.36.5.632
- Knowler WC, 2002, NEW ENGL J MED, V346, P393
- Legro RS, 2001, AM J MED, V111, P607, DOI 10.1016/S0002-9343(01)00948-2
- Maciel GAR, 2004, FERTIL STERIL, V81, P355, DOI 10.1016/j.fertnstert.2003.08.012
- Marcondes JAM, 2007, GYNECOL ENDOCRINOL, V23, P273, DOI 10.1080/09513590701192529
- Moghetti P, 2000, J CLIN ENDOCR METAB, V85, P139, DOI 10.1210/jc.85.1.139
- Moran LJ, 2003, J CLIN ENDOCR METAB, V88, P812, DOI 10.1210/jc.2002-020815
- Paradisi G, 2001, CIRCULATION, V103, P1410
- PASCALE RW, 1995, DIABETES CARE, V18, P1241, DOI 10.2337/diacare.18.9.1241
- Pekhlivanov B, 2006, Akush Ginekol (Sofiia), V45, P29
- Tang T, 2006, HUM REPROD, V21, P80, DOI 10.1093/humrep/dei311
- Fauser BCJM, 2004, HUM REPROD, V19, P41, DOI 10.1093/humrep/deh098
- VELAZQUEZ EM, 1994, METABOLISM, V43, P647, DOI 10.1016/0026-0495(94)90209-7